Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
04:10pm, Sunday, 29'th Mar 2020
After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coronavirus (COVID-19) news flow continued to dominate
Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM)
01:23am, Sunday, 29'th Mar 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Hedge Funds Were Selling Six Flags Entertainment Corp (SIX) Before The Coronavirus
07:49pm, Friday, 27'th Mar 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Here's Why The Best Is Yet to Come for Axsome Therapeutics
10:22am, Tuesday, 24'th Mar 2020
There are tangible near-term risks to the business in the face of the coronavirus pandemic, but investors with a long-term mindset could find this pharma stock attractive.
Analysts Are Bullish on Top Healthcare Stocks: CareDx (CDNA), ObsEva SA (OBSV)
11:18am, Monday, 23'rd Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CareDx (CDNA), ObsEva SA (OBSV) and Axsome Therapeutics
Analysts Are Bullish on Top Healthcare Stocks: CareDx (CDNA), ObsEva SA (OBSV)
11:18am, Monday, 23'rd Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CareDx (
CDNA
–
Research Report
), ObsEva SA (
OBSV
–
Research Report
) and Axsome Therapeutics (
A
Axsome Therapeutics (AXSM) Receives a Buy from H.C. Wainwright
12:13pm, Friday, 20'th Mar 2020
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics (AXSM), with a price target of $200.00. The
Axsome Therapeutics (AXSM) Receives a Buy from H.C. Wainwright
12:13pm, Friday, 20'th Mar 2020
In a report released today,
Ram Selvaraju
from H.C. Wainwright reiterated a
Buy
rating on Axsome Therapeutics (
AXSM
–
Research Report
), with a price target of
$200.00
. The company’s shares clos
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
11:37am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacte
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
08:14pm, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccin
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
12:00am, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
What's in Store for Axsome (AXSM) This Earnings Season?
03:33pm, Monday, 02'nd Mar 2020
On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
What's in Store for Axsome (AXSM) This Earnings Season?
03:33pm, Monday, 02'nd Mar 2020
On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
Sage Therapeutics Disappoints With Its Q4 Report
05:28pm, Thursday, 27'th Feb 2020
A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.
